Biotechnology News and Research

RSS

BioMimetic completes 100 day PMA meeting with FDA for Augment Bone Graft

BioMimetic Therapeutics, Inc. today announced it completed its 100 day Premarket Approval Application (PMA) meeting with the Food and Drug Administration (FDA) regarding the review of Augment™ Bone Graft for the treatment of foot and ankle fusions in the U.S. The FDA generally meets with the PMA sponsor approximately 100 days after the filing of the PMA with the purpose of discussing the status of the application.

9 Sep 2010

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Santarus, Inc., S2 Therapeutics, Inc. and VeroScience LLC today announced that they have entered into a distribution and license agreement granting Santarus exclusive rights to manufacture and commercialize CYCLOSET (bromocriptine mesylate) tablets in the U.S.

9 Sep 2010

Advaxis receives USPTO patent for Listeria vaccine

The U.S. Patent and Trademark Office has approved Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, intellectual property protection to patent application 11/223,945 - a live, attenuated Listeria vaccine that secretes novel fragments of the tumor antigen HER2/neu (human epidermal growth factor receptor 2), when using the company's proprietary listeriolysin O (LLO) fusion platform technology.

9 Sep 2010

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, will deliver four poster presentations on its compounds at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

9 Sep 2010

Team of scientists issues HIV vaccine strategy

The Council of the Global HIV Vaccine Enterprise on Tuesday released a new strategy for HIV vaccine research, which marked "the culmination of an 18-month effort that included the input of 400 scientists worldwide," VOA News reports (DeCapua, 9/7).

9 Sep 2010

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

9 Sep 2010

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer's disease (AD).

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

9 Sep 2010

BioSpace joins Delaware BioScience to launch online career center for life science markets

BioSpace has partnered with the Delaware BioScience Association to launch an online career center for life science markets including pharmaceuticals and biotechnology.

9 Sep 2010

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

BioMed Realty Trust, Inc. today announced that it has entered into definitive agreements to acquire five properties, comprised of 14 life science buildings with approximately 405,000 square feet of laboratory and office space, in San Diego's primary life science submarkets of University Towne Centre, Torrey Pines and Sorrento Valley.

8 Sep 2010

Vela Laboratories renews GMP certificate for analytical and Quality Control laboratories

Vela Laboratories, a provider of analytical services to the global biopharmaceutical industry, today announced the renewal of the GMP certificate for its analytical and Quality Control laboratories until 2013.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Mary Ann Liebert launches Childhood Obesity journal to promote clinical advances

Publisher Mary Ann Liebert announced the launch of Childhood Obesity to provide physicians, nurses, dietitians, diabetes educators, nutritionists, psychologists, educators and school nurses, community organizers, and policymakers with effective prevention and treatment strategies that promote environmental and policy changes, patient education and motivation tools, and clinical advances in the field.

8 Sep 2010

PPD establishes preferred provider relationships for conducting Phase I trials

PPD, Inc. today announced it has established preferred provider relationships with a network of sites across North America for conducting Phase I trials in patients to meet growing client demand for these services.

8 Sep 2010

Scientists gather to present research findings at ASHG 2010 Meeting

The world's top scientists and clinicians in the human genetics field will gather in Washington, D.C., to present their latest research findings at the 60th Annual Meeting of the American Society of Human Genetics, from Tuesday, November 2, through Saturday, November 6, 2010, at the Walter E. Washington Convention Center in D.C.

8 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

Scientists study behaviour of proteins that trigger age-related ailments

Scientists hope to gain insights into a range of age-related ailments, such as dementia, by examining the behaviour of proteins thought to trigger the conditions.Researchers from the University of Edinburgh are to study proteins found in the body to try to find out why these molecules can sometimes clump together as people get older. The clumps interfere with the biological processes that enable the body to function healthily.

8 Sep 2010

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome.

8 Sep 2010

Biotechnology News and Research

BioMimetic completes 100 day PMA meeting with FDA for Augment Bone Graft

Santarus, VeroScience enter agreement to commercialize CYCLOSET drug for type 2 diabetes

Advaxis receives USPTO patent for Listeria vaccine

NovaBay Pharmaceuticals to deliver new data on Aganocide compounds at ICAAC Conference

Team of scientists issues HIV vaccine strategy

ImmunoCellular Therapeutics announces long-term data from ICT-107 Phase I clinical trial for GBM

Researchers synthesize new compounds to reduce A-beta 42 peptide in Alzheimer's disease

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

BioSpace joins Delaware BioScience to launch online career center for life science markets

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

Vela Laboratories renews GMP certificate for analytical and Quality Control laboratories

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Mary Ann Liebert launches Childhood Obesity journal to promote clinical advances

PPD establishes preferred provider relationships for conducting Phase I trials

Scientists gather to present research findings at ASHG 2010 Meeting

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Scientists study behaviour of proteins that trigger age-related ailments

Silence Therapeutics receives two patents for RNA interference therapeutics

Can-Fite BioPharma opens IND with US-FDA for CF101 Phase 3 study in Dry Eye Syndrome

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News